<?xml version="1.0" encoding="utf-8" ?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN"
                  "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.2" article-type="other">
<front>
<journal-meta>
<journal-id></journal-id>
<journal-title-group>
<journal-title>Journal for Reproducibility in
Neuroscience</journal-title>
</journal-title-group>
<issn publication-format="electronic">2670-3815</issn>
<publisher>
<publisher-name>Publishers of Trial and Error</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<title-group>
<article-title>We need another 3R rule: repeat, repeat,
repeat!</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hulten</surname>
<given-names>Annika</given-names>
</name>
<xref ref-type="aff" rid="aff-0"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rannanpää</surname>
<given-names>Saara</given-names>
</name>
<xref ref-type="aff" rid="aff-0"/>
</contrib>
<aff id="aff-0">
<institution-wrap>
<institution>Janssen-Cilag Oy, Vaisalantie 2, 02130, Espoo,
Finland</institution>
</institution-wrap>
</aff>
</contrib-group>
<pub-date date-type="pub" publication-format="electronic">
<day>19</day>
<month>01</month>
<year>2021</year>
</pub-date>
<volume>2</volume>
<elocation-id>another-3r-rule</elocation-id>
<permissions>
<license license-type="CC-BY-SA" xlink:href="https://creativecommons.org/licenses/by-sa/4.0/">
<license-p>Creative Commons Attribution-ShareAlike 4.0 International
License</license-p>
</license>
</permissions>
<self-uri xlink:href="https://jrn.trialanderror.org/pub/another-3r-rule">This pub is available from https://jrn.trialanderror.org/pub/another-3r-rule</self-uri>
</article-meta>
</front>
<body>
<sec id="abstract">
  <title><bold>Abstract</bold></title>
  <p>There is consensus within the scientific community that replication
  studies are scientifically sound and bring added value and reliability
  to any discovery. It is also widely acknowledged that replications are
  not as common as they perhaps should be. The reasons for this vary
  depending on the stakeholder - here we will discuss the matter from
  the perspective of the pharmaceutical industry. However, the views
  expressed here are our own and do not represent the official
  standpoint of our employer or the industry in general. We will focus
  this commentary on the issues related to replications of the clinical
  part of the drug development, as our expertise is most closely related
  to this area, but the matter is equally relevant and important in the
  pre-clinical domain.</p>
  <graphic id="ni5w0x7b88w" mimetype="image" mime-subtype="png" xlink:href="https://assets.pubpub.org/r7s03hja/image-31691157741605.png" />
  <graphic id="nrbree3j3bo" mimetype="image" mime-subtype="png" xlink:href="https://assets.pubpub.org/pzrlppew/image-71691160815460.png" />
</sec>
</body>
<back>
</back>
</article>